) for a scientific commentary on this article.
Introduction
Reduced CSF amyloid-b 42 (amyloid-b 1-42 , referred to as CSF amyloid-b) and increased uptake of amyloid tracers visualized by PET (referred to as PET amyloid-b) (Klunk et al., 2004) are used as in vivo measurements of brain amyloid-b accumulation. This is a key feature of Alzheimer's disease and biomarker evidence of brain amyloid-b have been included in Alzheimer's disease research criteria (Albert et al., 2011; McKhann et al., 2011; Sperling et al., 2011; Dubois et al., 2014) .
Several studies have shown that low CSF, and high PET amyloid-b are correlated (Fagan et al., 2006 Forsberg et al., 2008; Koivunen et al., 2008; Grimmer et al., 2009; Tolboom et al., 2009) , and they are often interchangeable for the purpose of diagnosing Alzheimer's disease dementia Zwan et al., 2014) . These biomarkers are therefore often assumed to provide the same information. In this study, we investigated the alternative theory that CSF and PET amyloid-b provide partly different and independent information. There are several reasons to suspect this. First, PET amyloid-b is directly related to brain fibrillar amyloid-b (Ikonomovic et al., 2008) , whereas CSF amyloid-b is a marker of soluble amyloid-b and only indirectly related to fibrillar amyloid-b. In addition to fibrillar deposits, CSF amyloid-b may also be affected by variations in amyloid precursor proteinprocessing and amyloid-b production (May et al., 2011; Mattsson et al., 2012; Reiman et al., 2012; Potter et al., 2013) and non-fibrillar aggregation (Cairns et al., 2009; Schö ll et al., 2012) , and is for unknown reasons reduced in other medical conditions where plaques are not present, including neuroinflammation (Mattsson et al., 2009; Augutis et al., 2013) , Creuzfeldt-Jakob's disease and amyotrophic lateral sclerosis (Blennow and Hampel, 2003) . Second, although dichotomous CSF and PET amyloid-b classification often agree Zwan et al., 2014) , they classify a proportion of people discordantly (up to 25%, higher numbers in cognitively healthy people) (Cairns et al., 2009; Fagan et al., 2009; Schö ll et al., 2012; Landau et al., 2013) . Third, the overall correlation between CSF and PET amyloid-b is modest (Landau et al., 2013) and the correlation is very poor within the positive (low CSF, and high PET amyloid-b) and negative (high CSF amyloid-b and low PET amyloidb) biomarker ranges. Fourth, it has been suggested that CSF amyloid-b is reduced before an increase in PET amyloid-b , although not all studies have supported this (Landau et al., 2013) .
If CSF and PET amyloid-b partly reflect different aspects of amyloid metabolism-which is a core aspect of Alzheimer's disease pathophysiology (Hardy and Selkoe, 2002 )-they may be expected to provide partly independent information in Alzheimer's disease studies. We therefore tested the specific hypothesis that CSF and PET amyloid-b are independent predictors of other Alzheimer's disease measurements and features, including APOE e4 carriage status, Alzheimer's disease dementia diagnosis, cognitive deficits, hippocampal atrophy, brain hypometabolism, brain hypoperfusion, and increased levels of CSF tau biomarkers. We also tested if CSF and PET amyloid-b were differently related to these outcomes (suggesting that the amyloid-b biomarkers had different sensitivity to pathological changes during the disease course). Finally, in an exploratory analysis, we tested if a categorical classification using both CSF and PET amyloid-b (classifying subjects as concordant positive, discordant, or concordant negative) was associated with different outcomes, and if the frequency of discordant classification differed by disease stage.
Materials and methods

Study design
Michael W. Weiner, MD, VA Medical Centre and University of California San Francisco. ADNI is the result of efforts of many co-investigators from a broad range of academic institutions and private corporations, and subjects have been recruited from over 50 sites across the USA and Canada. The data used in this study included all subjects acquired in ADNI-2 with available baseline data on CSF and PET amyloid-b. For up-to-date information, see http://www.adni-info.org.
Cohort
Our study population consisted of cognitively healthy controls (cognitively normal) and people with subjective memory complaints (SMC), early mild cognitive impairment (MCI), late MCI (late MCI) or Alzheimer's disease dementia. Inclusion/exclusion criteria are described in detail at http://www.adni-info. org. Briefly, all subjects included in ADNI-2 were between the ages of 55 and 90 years, had completed at least 6 years of education, were fluent in Spanish or English, and were free of any significant neurological disease other than Alzheimer's disease. 
CSF biomarkers
All subjects underwent CSF sampling at baseline. Amyloid-b 42 , total tau and phosphorylated tau were measured using the multiplex xMAP Õ Luminex platform (Luminex Corp) with the INNOBIA AlzBio3 kit (Innogenetics) as described previously (Olsson et al., 2005; Shaw et al., 2009) . When indicated, subjects were classified as amyloid-b-positive or -negative using a previously defined cut-off (CSF amyloid-b 42 5 192 ng/l), which has been shown to be discriminative of brain amyloidb pathology in both PET imaging (Weigand et al., 2011) and two independent autopsy studies (Shaw et al., 2009; De Meyer et al., 2010) . For this study, we used the data files 'UPENNBIOMK5_10_31_13.csv', 'UPENNBIOMK6_07_02_ 13.csv' and 'UPENNBIOMK7.csv'.
Florbetapir PET
All subjects underwent florbetapir PET imaging at baseline. Images were acquired at baseline and processed as described previously (Landau et al., 2012) . Images were acquired 50 to 70 min post-injection, reconstructed immediately following the scan, and repeat scans were acquired if motion artefacts were detected. For quantification of florbetapir, 3 T 3D magnetization prepared rapid gradient echo (MPRAGE) MRI scans were used. MRI images were segmented and parcellated into individual cortical regions with FreeSurfer, and used to extract mean florbetapir uptake (standardized uptake value ratio) from grey matter within lateral and medial frontal, anterior and posterior cingulate, lateral parietal, and lateral temporal regions relative to uptake in the whole cerebellum (white and grey matter). The overall cortical mean standardized uptake value ratio was used in this study. When indicated, subjects were classified as PET amyloid-b-positive or -negative using a previously defined cut-off (41.11 standardized uptake value ratio) (Clark et al., 2011; Joshi et al., 2012; Landau et al., 2012) .
Cognition
We used the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog11) to assess cognitive function (numbers in brackets indicate data points in each diagnostic group, also presented below for other measurements) at baseline ( 
Fluorodeoxyglucose PET
FDG image data were acquired at baseline (cognitively normal 161, SMC 67, early MCI 268, late MCI 150, Alzheimer's disease 119) and after 2 years (cognitively normal 80, early MCI 125, late MCI 39, Alzheimer's disease 13) and processed as described previously (Landau et al., 2012) . Images were acquired 30 to 60 min post-injection. The average FDG-PET from three regions (temporal regions, lateral parietal regions, and posterior cingulate cortex) was used in this study. Data were expressed relative to the mean in a reference region (pons and cerebellar vermis) (Landau et al., 2011) . and 3 (cognitively normal 1, early MCI 37) years using 3 T MRI scanners with a standardized protocol including T 1 -weighted MRI scans using a sagittal volumetric MPRAGE sequence (Jack et al., 2008) . Data on hippocampal volume (averaged right and left) were used in this study. Quantification was done in an automated pipeline using FreeSurfer software package version 5.1 (http://surfer.nmr.mgh.harvard.edu/fswiki) (Fischl et al., 2002 (Fischl et al., , 2004 ).
Structural MRI
Arterial spin labelling MRI
Cerebral blood flow was measured by arterial spin labelling MRI at baseline (cognitively normal 39, SMC 9, early MCI 61, late MCI 40, Alzheimer's disease 22) and processed as described online at www.loni.usc.edu and as reported previously . In short, arterial spin labelling MRI was performed on 3 T MRI machines using a pulsed method with echo-planar imaging (Luh et al., 1999) . All ASL images were processed using a largely automated pipeline which included motion correction, computation of perfusion weighted images, co-registration to structural MRI and correction for partial grey/white matter volume effects. In this study, we used data on temporal cerebral blood flow (a combination of cerebral blood flow from all temporal lobe FreeSurfer regions, averaged between right and left hemisphere), as we previously found associations between amyloid-b and several temporal lobe regions .
Statistical analysis
Continuous CSF and PET amyloid-b were used as predictors of diagnosis, APOE e4 carriage status, CSF total tau, CSF phosphorylated tau, cerebral blood flow, hippocampal volume, FDG-PET and ADAS-cog. Three models were generated for each response, using CSF amyloid-b, PET amyloid-b, or CSF and PET amyloid-b as predictors. Non-parametric 95% confidence intervals (CI) of coefficients were estimated from the percentiles of bootstrap samples. A 95% CI that excluded zero when CSF or PET amyloid-b was adjusted for the other modality indicated a partially independent association with the response. Because CSF and PET amyloid-b were correlated we used ridge regression, which provides stable estimates of coefficients of correlated predictors (Friedman et al., 2009) . To test if the combination of CSF and PET amyloid-b improved model fits, we also reported the Akaike information criterion (AIC). AIC is a measure of the relative quality of a statistical model for a given set of data, and provides a means for model selection. AIC is defined as 2 k À 2 ln (L), where k is the number of parameters and L is the maximized value of the likelihood function for the model. A lower AIC represents a better fit (penalized for the number of predictors to avoid over-fitting). A difference in AIC (DAIC) of 0-2, 4-7, and 410 represent some evidence, considerable evidence, and very strong evidence, respectively, for differences between two models (Burnham and Anderson, 2002) . All analyses were done first on all subjects and then separately on subjects within the concordant 'positive' (CSF amyloid-b 42 5 192 and florbetapir PET 4 1.11 standardized uptake value ratio) and 'negative quadrants'. Except for models of diagnosis (cognitively normal versus Alzheimer's disease), all analyses were done on all diagnoses combined.
For all analyses described above, CSF and PET amyloid-b were used as continuous data. In a second step we combined the two amyloid-b modalities into four categories by dichotomizing CSF and PET amyloid-b data using a priori cut-offs and combining them into concordant negative (CSFÀPETÀ), discordant with CSF positivity (CSF+PETÀ), discordant with PET positivity (CSFÀPET+) and concordant positive (CSF+PET+). The chi-square test was used to test if the proportion of discordance differed by diagnostic group. We repeated the regression analyses described above using the categorical predictor, with CSFÀPETÀ as the reference category. This was done within the diagnostic groups. These exploratory analyses were corrected for multiple comparisons using false discovery rate correction.
Logistic regression was used for diagnosis and APOE e4 (cross-sectional dichotomous data). Ordinary least square regression was used for cerebral blood flow, CSF phosphorylated tau and total tau (cross-sectional continuous data). Linear mixed effects was used for hippocampal volume, FDG-PET and ADAS-cog (longitudinal continuous data). All models were adjusted for age and sex. Additionally, temporal cerebral blood flow was adjusted for cerebral blood flow in a reference region (precentral cerebral blood flow), hippocampal volume was adjusted for total intracranial volume, and ADAS-cog was adjusted for education (years). All linear mixed effects models included the interaction terms Time Â CSF amyloid-b and/or Time Â PET amyloid-b, the corresponding main effects, and random intercepts and slopes. Mixed effects models were fit using the maximum likelihood criterion, as this is preferred for model comparison (Bates, 2010) but the overall results were similar when refitting the models with the restricted maximum likelihood estimation criterion.
The model assumptions were assessed by evaluating normality and homoscedasticity of residuals with q-q plots and plots of residuals versus fitted values. Estimates from the full sample were compared to bootstrapped estimates. To test if variables were related to study drop-out (missing data for ADAS-cog, hippocampal volume and FDG-PET) we used a generalized mixed effects model with a binomial response, with age, sex, education, CSF amyloid-b, and PET amyloid-b as predictors of 'missing data' [a missing indicator (true/false) for each study visit]. All tests were two-sided, and significance was determined at P 5 0.05. All statistics were done using R (v.3.0.1, The R Foundation for Statistical Computing).
Results
Study demographics are shown in Table 1 . As explained above, the available follow-up data varied for longitudinal MRI, FDG-PET and ADAS-cog. Amyloid-b measures were not associated with missing data, except for an association between high PET amyloid-b and missing longitudinal MRI data (P = 0.039). This was driven mainly by the patients with Alzheimer's disease dementia, who had high PET amyloid-b levels and relatively short follow-up. Thus, the effects of PET amyloid-b on longitudinal atrophy might be slightly underestimated, although mixed-effect models are robust to this type of covariate associated missing data (Little and Rubin, 2002) . small hippocampal volume, hypometabolism and low ADAS-cog. For cerebral blood flow, only CSF amyloid-b was an independent predictor. Figure 1 shows coefficients for all outcomes (log-odds ratios for binary outcomes, diagnosis and APOE e4). For interpretation, note that CSF and PET amyloid-b and all continuous responses were standardized (centred and scaled), and that the sign of CSF amyloid-b was changed to facilitate comparisons between amyloid-b modalities. Therefore, a positive coefficient indicates a positive association between high amyloid-b load (by any modality) and the response of interest.
To interpret the results for binary outcomes, consider for example PET amyloid-b and Alzheimer's disease diagnosis. The adjusted log-odds ratio was 0.9 (95% CI 0.8 to 1.1), indicating that (i) high PET amyloid-b was associated with increased risk of Alzheimer's disease dementia (the coefficient was positive); (ii) high PET amyloid-b provided information that was partially independent from CSF amyloid-b (the 95% CI adjusted for CSF amyloid-b, did not include zero); and (iii) the risk (log-odds ratio) of Alzheimer's disease dementia increased on average 0.9 per standard deviation increase in PET amyloid-b. Exponentiation of the logodds ratio gives the odds ratio (OR = e 0.9 ) 2.5, which can be interpreted as a 150% increase in the odds for having Alzheimer's disease dementia for each standard deviation increase in PET amyloid-b. To interpret the results for continuous outcomes, consider for example CSF amyloid-b and baseline hippocampal volume. The adjusted b-coefficient was À0.17 (95% CI À 0.23 to À 0.11), indicating that (i) low CSF amyloid-b (recall the sign of CSF amyloid-b was changed) was associated with small baseline hippocampi; (ii) low CSF amyloid-b provided partially independent information (the 95% CI adjusted for PET amyloid-b, did not include zero); and (iii) the mean hippocampal volume was 0.17 SD smaller for each standard deviation decrease in CSF amyloid-b.
These analyses were done without adjusting for diagnostic group. When adjusting for diagnosis the effects of CSF and PET amyloid-b were slightly reduced as expected, because diagnosis is associated with amyloid-b. However, CSF and PET amyloid-b remained partially independent predictors of APOE e4, CSF total tau, CSF phosphorylated tau, hippocampal volume (at baseline and over time), ADAS-cog (at baseline and over time) and FDG-PET (at baseline) ( Supplementary Fig. 1 ).
Change in effects of CSF and PET amyloid-b when combining them as predictors Figure 1 also shows the relative change in coefficients when adjusting CSF and PET amyloid-b for each other (right y-axis). The adjusted coefficients were always reduced, as CSF and PET amyloid-b partly provide the same information. However, the magnitude of the changes differed markedly between modalities and responses. For example, for APOE e4, the PET amyloid-b coefficient was reduced 52% by adjusting for CSF amyloid-b, while the CSF amyloid-b coefficient was reduced 25% by adjusting for PET amyloid-b, therefore the difference in reduction was 27% (95% CI 3.3 to 49), indicating a stronger relationship between CSF amyloid-b and APOE e4. Interpreting the data this way, CSF amyloid-b was more closely related to APOE e4; and PET amyloid-b was more closely related to CSF total tau (difference 50%, 95% CI 25 to 78), phosphorylated tau (37%, 95% CI 15 to 64) and ADAS-cog (baseline 24%, 95% CI À 5.4 to 53; slope 25%, 95% CI À 2.5 to 53; and the two modalities were about equally related to diagnosis (14%, 95% CI À12 to 45), hippocampal volume (baseline 0%, 95% CI À 30 to 37; slope 9%, 95% CI À 22 to 45) and FDG-PET (baseline 9%, 95% CI À22 to 41; slope À5%, 95% CI À146 to 108). For cerebral blood flow, the CSF amyloid-b coefficient was only reduced by 4% whereas the PET amyloid-b coefficient was reduced by 91%, giving a difference in reduction of 87%, but the 95% CI for this difference was wide (À 113 to 550).
Improved model fits when combining CSF and PET amyloid-b as predictors
The left columns of Table 2 show AIC for all models applied to subjects in all biomarker quadrants, and DAIC for comparisons of models with the same responses. Combining the two amyloid-b modalities was preferable for most responses (DAIC 5 4), and there was very strong support (DAIC 5 10) for the combination to predict APOE e4, hippocampal volume, ADAS-cog and CSF phosphorylated tau. 
Effects of CSF and PET amyloid-b in the positive biomarker range
We repeated the analyses within the 'positive biomarker quadrant' (CSF amyloid-b 42 5 192 ng/l and florbetapir PET 4 1.11 standardized uptake value ratio). Here, PET amyloid-b was no longer an independent predictor of APOE e4, but the two amyloid-b modalities were partially independent predictors of diagnosis, CSF total tau, CSF phosphorylated tau, hippocampal volume (baseline and follow-up), ADAS-cog (baseline and follow-up), and FDG-PET (baseline) (Supplementary Fig. 2 ). As seen in Table 2 the AIC analyses demonstrated that the combination of the two amyloid-b modalities was preferred before either measure alone to predict hippocampal volume, ADAS-cog and total tau within the 'positive biomarker quadrant' (DAIC 5 4). The relative change when adjusting CSF and PET amyloid-b for each other did not differ between modalities (comparing b-ratios on the secondary y-axis of Supplementary Fig. 2 ). Alzheimer's disease diagnosis we compared Alzheimer's disease dementia versus cognitively normal. For APOE e4 we compared subjects with the APOE e4 allele versus subjects without the APOE e4 allele. For cerebral blood flow (CBF), ADAS-cog, hippocampal volume and FDG-PET we used these parameters as continuous outcomes. Coefficients are shown both for unadjusted models (black, closed symbols) and for models adjusted (red, open symbols) for the other modality. The error bars are 95% CI. If the adjusted 95% CI excluded zero it indicated a significant independent effect for that modality on the response. The relative change when adjusting for the other modality is shown on the right y-axis. Differences between amyloid-b groups in brain structure, cognition and CSF tau When examining concordant negative, discordant and concordant positive individuals, we found that 21% of cognitively normal/SMC, 13% of early MCI, 11% of late MCI and 6% of Alzheimer's disease dementia patients were discordant (Fig. 2 ). Most discordant subjects had isolated low CSF amyloid-b. Concordance increased significantly with disease stage (P 5 0.001). The table shows AIC for models with only CSF amyloid-b, only PET amyloid-b, or both CSF amyloid-b, only PET amyloid-b as predictors. AIC is a measure of model fit and is penalized for including additional predictors (it thereby protects against overfitting). A small AIC is preferable when comparing models (but the absolute AIC cannot be compared between models with different data). The smallest AIC for each response is indicated in bold in the table. For each model, the DAIC is the difference between that model's AIC and the AIC of the model when including both CSF and PET amyloid-b as predictors. DAIC 0-2, 4-7, and 410 represent some evidence, considerable evidence, and very strong evidence, respectively, for difference between two models (Burnham and Anderson, 2002) . The concordant negative often differed from the concordant positive group on several measures, but not from any of the discordant groups (when adjusting for multiple comparisons). All of the following comparisons use the CSFÀPETÀ group as reference category. APOE e4 carriage status was more common in CSF+PET+ cognitively normal (OR = 1.71, P = 0.0037), SMC (OR = 3.36, P = 0.0037), early MCI (OR = 2.51, P 5 0.0001), late MCI (OR = 3.43, P 5 0.0001) and Alzheimer's disease (OR = 3.42, P = 0.014), and in CSF+PETÀ early MCI (OR = 1.65, P = 0.0055). For ADAS-cog, baseline scores were elevated in CSF+PET+ late MCI (b = 3.35, P = 0.0020), and deficits accelerated over time in CSF+PET+ early MCI (b = 0.55, P = 0.034) and late MCI (b = 2.60, P = 0.00011). For hippocampus, baseline volumes were reduced in CSF+PET+ late MCI (b = À384, P = 0.0018) and shrinkage accelerated over time in CSF+PET+ early MCI (b = À 33.1, P = 0.034). For CSF phosphorylated tau, levels were increased in CSF+PET+ cognitively normal (b = 11.0, P = 0.0047), SMC (b = 30.5, P 5 0.0001), early MCI (b = 25.8, P 5 0.0001) and late MCI (b = 30.8, P 5 0.0001). CSF total tau levels were similar to CSF phosphorylated tau but with slightly less pronounced group differences (data not shown). For FDG-PET, the signal was lower in CSF+PET+ at baseline in late MCI (b = À0.085, P = 0.036), and Alzheimer's disease (b = À 0.17, P = 0.021) and over time in late MCI (b = À 0.037, P = 0.034). Cerebral blood flow did not differ by amyloid-b group in any diagnostic group. These tests were corrected for multiple comparisons (using false discovery rate).
Discussion
Our main findings were that (i) CSF and PET amyloid-b provided partially independent information when predicting most Alzheimer's disease-associated measures (even within amyloid-b positive subjects, defined by combined CSF and PET amyloid-b positivity); (ii) CSF and PET amyloid-b were related to multiple measures in different ways (for example, APOE e4 was preferentially associated with CSF amyloid-b); (iii) CSF and PET amyloid-b discordance (mainly consisting of isolated CSF amyloid-b positivity) was common in cognitively normal and SMC subjects; and (iv) concordant CSF and PET amyloid-b positivity was common in late stage disease (late MCI and Alzheimer's disease) and associated with most other Alzheimer's disease measures. The results were in agreement with our hypothesis that the two amyloid-b modalities provide partially independent information. The results may support CSF amyloid-b as a more sensitive marker of very early disease and PET amyloid-b as a more sensitive marker of disease progression and down-stream pathology.
The first finding was that CSF and PET amyloid-b were partially independent predictors of diagnosis, APOE e4, high CSF total tau and phosphorylated tau, hypometabolism, hippocampal atrophy and (for CSF) reduced cerebral blood flow. Most of these are well established characteristics of Alzheimer's disease. The fact that the two amyloid-b modalities were partially independent predictors across most outcomes supports our underlying theory that they partly represent different aspects of Alzheimer's disease pathology. This likely includes several different but important aspects of amyloid metabolism, and could for example be related to differences across disease stages in the composition of amyloid plaques (Yamaguchi et al., 1989; Schmidt et al., 1994) . CSF and PET amyloidb predicted several Alzheimer's disease features even when restricting the analysis to people with strong evidence of amyloid-b pathology (combined CSF and PET amyloid-b positivity). The strongest relationships were between amyloid-b biomarkers and hippocampal volume and ADAS-cog, suggesting that amyloid-b metabolism continues to be related to brain injury and cognitive deficits even after the first appearance of fibrillar amyloid-b. This is in line with recent reports of dynamic changes in amyloid-b biomarkers also in demented amyloid-b-positive patients (Toledo et al., 2013; Villemagne et al., 2013) .
The second finding was that CSF amyloid-b was more strongly related to APOE e4, whereas PET amyloid-b was more strongly related to ADAS-cog, CSF total tau and CSF phosphorylated tau. There was also some evidence that CSF amyloid-b was more strongly related to reduced cerebral blood flow, as CSF amyloid-b (but not PET amyloid-b) remained a significant predictor of cerebral blood flow when both modalities were included as predictors. There are several possible interpretations of these findings. First, although amyloid-b load as measured by PET correlates with reduced cerebral blood flow , the fact that CSF amyloid-b rather than PET amyloid-b was preferentially associated with cerebral blood flow suggests that this association goes beyond the presence of overt plaque pathology. For example, it could be related to arterial blood flow regulating the CSF-brain interstitial fluid exchange (Iliff et al., 2013) . Second, the strong relationship between APOE e4 and CSF amyloid-b suggests a role for APOE e4 in amyloid-b metabolism that goes beyond fibrillar amyloid-b, perhaps including formation of other types of aggregates, such as amyloid-b oligomers, or epitope masking due to binding of amyloid-b with chaperoning APOE protein (Verghese et al., 2011; Slemmon et al., 2012) . Third, the strong relationship between PET amyloid-b and total tau, phosphorylated tau and ADAS-cog suggests that PET amyloid-b may be a better measurement than CSF amyloid-b of late stage progression of pathology.
The third finding was that CSF and PET amyloid-b mismatch classification was dependent on diagnostic category and seen in 21% of cognitively normal and SMC subjects, 10-14% in MCI, and 6% of Alzheimer's disease dementia. For the cognitively normal group, the discordance was slightly higher than in a previous analysis of this cohort (including about half the subjects, n = 374) (Landau et al., 2013) , but was in agreement with other studies where 15-25% of healthy controls were discordantly classified Zwan et al., 2014) . Most mismatched people in our study had low CSF amyloid-b without increased PET amyloid-b [this may vary between cohorts and cut-offs Zwan et al., 2014) ]. A number of factors could cause isolated low CSF amyloid-b, including non-fibrillar brain deposits (Cairns et al., 2009; Schö ll et al., 2012) , reduced amyloid-b 42 production (Mattsson et al., 2012) , other inflammatory and degenerative diseases reducing CSF amyloidb 42 without formation of fibrillar deposits (Blennow and Hampel, 2003; Mattsson et al., 2010; Augutis et al., 2013) , and false low values due to technical variability (Mattsson et al., 2011 (Mattsson et al., , 2013 . Another possibility is that CSF amyloid-b could be sensitive to amyloid pathology primarily in specific regions of the brain, although several studies argue against this (Grimmer et al., 2009; . Isolated increased PET amyloid-b may be due to unspecific retention of the amyloid ligand, false high levels due to technical issues (processing errors) and perhaps also physiologically high CSF amyloid-b levels in individuals who remain above the CSF cut-off even in the presence of fibrillar amyloid-b. Note that we propose that CSF-PET discordance contains relevant information, but it may be possible to construct a CSF measurement that is more specific for fibrillar amyloid-b (with less mismatches) by adjusting CSF amyloid-b 42 for CSF amyloid-b 40 , removing some of the variance due to overall amyloid-b production and clearance (Hansson et al., 2007; Wiltfang et al., 2007) . The development of novel assays for CSF amyloidb 42 will likely reduce errors due to technical variability (Korecka et al., 2014; Leinenbach et al., 2014) . One study found very high concordance between low CSF amyloid-b and increased PET amyloid-b in patients with MCI (Palmqvist et al., 2014) , although it is possible that the concordance may vary depending on pre-analytical and analytical factors for CSF amyloid-b 42 measurements (Oskar Hansson, personal communication) . The fact that the proportion of discordant cases dropped with disease stage argues against technical variability in CSF or PET measurements as the primary source of discordance in this study. Irrespective of cause, this and previous reports point to a CSF-PET mismatch frequency of $20% in cognitively healthy subjects, which is relevant to consider when designing preclinical trials using amyloid-b biomarkers to identify early stage brain pathology. Mismatch was not associated with increased risk of longitudinal brain atrophy or cognitive decline over the time period studied here. However, the finding that low CSF amyloid-b but normal PET amyloid-b was most common in cognitively normal subjects and less common in advanced disease stages is compatible with a model where low CSF amyloid-b appears earlier than high PET amyloid-b. This is also supported by the finding that the risk factor APOE e4 was preferentially associated with CSF amyloid-b whereas downstream measures, including cognitive deficits and CSF tau biomarkers, were preferentially associated with PET amyloid-b.
The final finding was that concordant amyloid-b classification was associated with high risk of most other Alzheimer's disease measures. This is in agreement with the previous literature, which has linked amyloid-b pathology as measured by either modality to many features of Alzheimer's disease. By examining CSF and PET amyloid-b simultaneously we increased our power to detect effects as mismatch cases likely add noise to studies only including one modality. In Alzheimer's disease dementia, most patients were concordant positive. Reassuringly, the few amyloid negative Alzheimer's disease dementia patients (unlikely to have Alzheimer's disease according to modern criteria) were stable in ADAS-cog. Curiously, they showed the same rate of hippocampal shrinkage as amyloid-positive patients (data not shown), but note that the number of negative Alzheimer's disease dementia patients was small.
A possible limitation was the influence of data points close to the cut-offs, but the results were stable when excluding individuals with CSF or PET amyloid-b within 5% of the respective cut-offs (data not shown). Another possible limitation when comparing different models is the risk of over-fitting models with multiple predictors. However, AIC, which was used for model comparison, penalizes for additional predictors and thereby protects against this cause of over-fitting. Another limitation to the generalizability of the results of this study is that medical conditions where CSF amyloid-b 42 is known to be reduced without presence of plaques [including neuroinflammation (Mattsson et al., 2009; Augutis et al., 2013) Creuzfeldt-Jakob's disease and amyotrophic lateral sclerosis (Blennow and Hampel, 2003) ], where not included in this cohort, although patients with such conditions would have been interesting to investigate with a combination of CSF and PET amyloid-b. Finally, we performed a large number of tests of the effects of continuous CSF amyloid-b and PET amyloidb on different outcomes without correcting for multiple comparisons. Our results pointed strongly at associations between amyloid-b measures and deleterious effects (this was seen in 41 of 44 comparisons in the main analysis, presented in Fig. 1 ). Taken together with the previous literature that also supports associations between amyloid-b and brain injury and impaired cognition, we find it exceedingly unlikely that these significant associations are due to type I error. An adjustment for multiple comparisons would therefore risk an overcorrection. In contrast, the more exploratory comparisons within diagnostic groups using the classification of concordant and discordant CSF-PET amyloid-b as a categorical predictor were adjusted for multiple comparisons.
In sum, we found that CSF and PET amyloid-b show partially independent associations with a wide range of Alzheimer's disease measures, supporting our theory that CSF and PET amyloid-b to some extent represent different aspects of Alzheimer's disease-relevant amyloid metabolism. Combining CSF and PET amyloid-b may improve prediction of clinical and pathological aspects of Alzheimer's disease. CSF-PET mismatch was dominated by isolated reduced CSF amyloid-b and was most common in controls.
Furthermore, reduced CSF amyloid-b was more strongly associated with APOE e4 and increased PET amyloid-b was more strongly associated with CSF total tau and phosphorylated tau, which are markers of neurodegeneration, and ADAS-cog, which is an indicator of clinical disease progression. Taken together, this suggests that reduced CSF amyloid-b may represent an earlier signal than increased brain amyloid-b detected by PET, and that PET amyloid-b may be a more sensitive marker of disease progression during the development of Alzheimer's disease pathology.
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